Current Report Filing (8-k)
July 25 2019 - 11:27AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 24, 2019
MEDICINOVA, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-33185
|
|
33-0927979
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
4275 EXECUTIVE SQUARE,
SUITE 300, LA JOLLA, CA
|
|
92037
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (858)
373-1500
Check the
appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2.
below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
|
|
|
|
|
Common Stock, $0.001 par value
|
|
MNOV
|
|
The Nasdaq Stock Market LLC
|
(Title of each class)
|
|
(Trading symbol(s))
|
|
(Name of each exchange on
which registered)
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On July 24, 2019, the Board of Directors (the Board) of MediciNova,
Inc. (the Company) authorized and appointed Dr. Kazuko Matsuda as a member of the Board as a Class II director, effective immediately. The Company issued a press release announcing the appointment of Dr. Matsuda, a copy of
which is furnished as Exhibit 99.1 to this Current Report on Form
8-K
and incorporated by reference in this Item 5.02.
There are no family relationships between Dr. Matsuda and any of the Companys directors or executive officers and Dr. Matsuda does not have
any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation
S-K. There
were no arrangements or understandings by which Dr. Matsuda
was named a director.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MEDICINOVA, INC.
|
|
|
|
|
DATE: July 25, 2019
|
|
|
|
By:
|
|
/s/ Carla Reyes
|
|
|
|
|
|
|
Carla Reyes
|
|
|
|
|
|
|
Chief Financial Officer
|
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Sep 2023 to Sep 2024